Drugs / DTaP-IPV-Hep B-PRP~T combined vaccine
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02094833 | Mar 2014 → Apr 2016 | diphtheria, haemophilus infectious disease, hepatitis B virus infection, pertussis +2 | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 3 | NCT01444781 | Sep 2011 → Apr 2013 | diphtheria, hepatitis B virus infection, pertussis, poliomyelitis +1 | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DTaP-IPV-Hep B-PRP~T combined vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01444781 ↗ |
| Modality | Vaccine | “DTaP-IPV-Hep B-PRP~T combined vaccine + Pneumococcal polysaccharide” NCT01444781 ↗ |
| Route | Intramuscular | “0.5 mL, Intramuscular each into the right and left deltoid muscle” NCT01444781 ↗ |